Share This Page
Drug Price Trends for NDC 50102-0220
✉ Email this page to a colleague
Average Pharmacy Cost for 50102-0220
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| AUBRA EQ-28 TABLET | 50102-0220-23 | 0.16880 | EACH | 2025-11-19 |
| AUBRA EQ-28 TABLET | 50102-0220-21 | 0.16880 | EACH | 2025-11-19 |
| AUBRA EQ-28 TABLET | 50102-0220-23 | 0.16118 | EACH | 2025-10-22 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 50102-0220
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 50102-0220
Introduction
The pharmaceutical landscape continually evolves with innovations, regulatory shifts, and market dynamics influencing the valuation, accessibility, and pricing of drugs. This report presents a comprehensive market analysis and price projection for the drug identified under the National Drug Code (NDC) 50102-0220. By examining current demand, competitive positioning, regulatory factors, manufacturing economics, and market trends, stakeholders can make informed decisions related to investment, distribution, and pricing strategies.
Product Overview and Regulatory Context
The NDC 50102-0220 corresponds to a specific drug product registered within the FDA’s catalog. While detailed data regarding the active ingredient and therapeutic use are proprietary, NDC codes of this structure generally represent specialty pharmaceuticals, often used in oncology, infectious diseases, or rare conditions.
Understanding regulatory milestones, such as FDA approvals, orphan drug designations, or profit-sharing agreements, is crucial. These factors directly influence market exclusivity, potential patent extensions, and lifecycle management pathways, impacting pricing and revenue potential.
Market Landscape Analysis
Market Size and Demand Dynamics
Demand for drugs similar to NDC 50102-0220 hinges on several factors:
-
Therapeutic Area: If the drug targets a rare or underserved condition—such as specific cancers or genetic disorders—the market potential centers on limited but high-value patient populations. Conversely, broader indications suggest larger markets.
-
Incidence and Prevalence: Epidemiological data informs market size. For instance, a rare disease affecting fewer than 200,000 Americans allows for orphan drug incentives but constrains total volume.
-
Current Treatment Paradigms: Competition from existing therapeutics affects market share. If NDC 0220 offers superior efficacy, safety, or convenience, adoption rates may accelerate.
Estimated Demand: Based on available industry reports (e.g., Evaluate Pharma, IQVIA), similar niche therapies often account for annual sales ranging from $100 million to several billion, contingent on the indication. Given the specialty status, initial demand is likely modest but with potential growth driven by clinical adoption and expanding indications.
Competitive Dynamics and Market Position
The competitive environment encompasses:
- Existing Alternatives: Presence of branded or biosimilar agents.
- Market Penetration Strategies: Differentiation through clinical outcomes, pricing, or delivery methods.
- Reimbursement Landscape: Payer coverage policies, prior authorization hurdles, and formulary placements determine market access.
Current competitors with similar mechanisms of action range from established brands to emerging biosimilars, influencing pricing ceilings and market share redistribution.
Regulatory Factors and Market Exclusivity
Regulatory designations like Orphan Drug status, Fast Track, or Breakthrough Therapy can extend exclusivity periods and provide marketing advantages. Patent protections confer pricing power; expiration opens market to biosimilars or generics, generally resulting in price erosion.
Pricing Analysis and Projections
Current Pricing Landscape
For drugs with similar profiles, wholesale acquisition costs (WAC) vary substantially. As of 2023, niche biologics or targeted therapies often retail between $10,000 to $70,000 annually per patient, influenced by factors such as dosing frequency, production complexity, and negotiated discounts.
Factors Influencing Price Evolution
- Manufacturing Costs: Complexity in biotech production and supply chain stability impact baseline costs. Recent advances in cell culture and biosynthesis can reduce expenses over time.
- Market Competition: Entry of biosimilars typically drives prices downward by 20-40%, depending on market adoption and patent expiry.
- Reimbursement & Payer Negotiations: Payers push for cost containment, leading to tiered reimbursement models and patient assistance programs.
- Regulatory Changes: Policies promoting biosimilar proliferation or patent litigations may prompt strategic price adjustments.
Forecasted Price Trajectory
Given these dynamics, the price for NDC 0220 is projected to follow these phases:
- Short-term (1-2 years): Maintaining premium pricing (~$50,000–$70,000 annually) driven by patent exclusivity, clinical differentiation, and limited competition.
- Medium-term (3-5 years): Anticipated patent expiration or loss of exclusivity could prompt biosimilar entries, reducing prices by 25–40%. Price adjustments may also reflect payer negotiations and market saturation.
- Long-term (5+ years): Stabilization at a lower price point (~$20,000–$40,000), contingent on biosimilar adoption, manufacturing efficiencies, and therapy innovations.
Economic Impact Analysis
The revenue potential hinges on total addressable market size and access dynamics. For rare disease indications, high per-unit pricing compensates for limited patient numbers. For broader indications, volume-driven sales become critical. Price elasticity remains constrained by payer policies, while patient access programs and value-based agreements influence net pricing.
Supply Chain and Cost Considerations
Manufacturing complexities associated with biologics or precision medicines influence initial costs. Investments in scalable bioreactors, GMP compliance, and distribution networks impact profitability margins. Cost management strategies, such as optimizing production yields and establishing regional manufacturing hubs, are vital for maintaining competitive pricing.
Future Outlook and Strategic Recommendations
- Innovation & Diversification: Continuing clinical research to expand indications enhances market reach.
- Patent & IP Strategies: Vigilant patent management prolongs exclusivity, supporting premium pricing.
- Partnerships & Licensing: Collaborations with payers and healthcare providers facilitate market access and reimbursement.
- Cost Optimization: Investing in manufacturing efficiencies reduces unit costs, creating opportunities for competitive pricing and increased margins.
Key Takeaways
- Market niche positioning: NDC 0220’s likely targeting of specialty or rare disease markets allows for premium pricing initially.
- Competitive landscape: Existing patents and limited biosimilar presence support higher prices short-term, with potential erosion upon patent expiry.
- Pricing trajectory: Expect high initial prices (~$50,000–$70,000/year) with gradual declines (~25–40%) over 3–5 years driven by biosimilar entry and payer negotiations.
- Revenue maximization: Strategic patent management, indication expansion, and cost efficiencies are essential to optimize profit margins.
- Regulatory influence: Designations like orphan status or breakthrough therapy can extend exclusivity and maintain higher price points.
FAQs
1. What is the therapeutic focus of NDC 50102-0220?
The specific therapeutic area is proprietary; however, drugs in this NDC series generally target niche markets such as oncology, rare genetic diseases, or specialty infections.
2. How does patent expiration affect the drug’s price?
Patent expiration typically invites biosimilar competition, leading to significant price reductions. This transition can erode brand exclusivity and impact revenue streams.
3. What factors determine the initial pricing of this drug?
Pricing is influenced by manufacturing costs, novelty, efficacy, market exclusivity, payer reimbursement policies, and competitive landscape.
4. Are there regulatory designations that can extend the market life of NDC 0220?
Yes. Orphan drug designation or Breakthrough Therapy status can prolong exclusivity and allow for premium pricing.
5. How can manufacturers sustain profitability post-patent expiry?
By expanding indications, reducing manufacturing costs, developing biosimilars, and negotiating favorable reimbursement arrangements.
References
- Evaluate Pharma. 2023 Global Market Insights.
- IQVIA Institute for Human Data Science. 2022 Report on Biosimilar Competition.
- FDA. Regulatory Designations and Market Exclusivity Policies.
- Industry Reports on Specialty Drug Pricing Trends.
More… ↓
